Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,338
  • Shares Outstanding, K 61,948
  • Annual Sales, $ 16,150 K
  • Annual Income, $ -77,330 K
  • EBIT $ -86 M
  • EBITDA $ -89 M
  • 60-Month Beta 1.18
  • Price/Sales 4.68
  • Price/Cash Flow N/A
  • Price/Book 0.73

Options Overview Details

View History
  • Implied Volatility 189.22% ( -19.88%)
  • Historical Volatility 77.45%
  • IV Percentile 39%
  • IV Rank 20.31%
  • IV High 889.90% on 03/17/25
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 33
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,499
  • Open Int (30-Day) 2,149

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.34
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -24.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1300 +7.52%
on 05/21/25
1.4100 -13.83%
on 06/10/25
+0.0050 (+0.41%)
since 05/16/25
3-Month
0.8332 +45.82%
on 04/07/25
1.4100 -13.83%
on 06/10/25
+0.1050 (+9.46%)
since 03/14/25
52-Week
0.8332 +45.82%
on 04/07/25
5.3899 -77.46%
on 11/11/24
-2.5750 (-67.94%)
since 06/14/24

Most Recent Stories

More News
This Natural Killer Treatment Could Help Transform How Cancer is Treated

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic...

PYXS : 1.2100 (+0.83%)
IOVA : 2.09 (-6.70%)
BTAI : 1.6800 (+7.69%)
GTBP : 2.81 (-1.06%)
FATE : 1.2250 (-3.92%)
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

PYXS : 1.2100 (+0.83%)
Pyxis Oncology to Participate in Two Upcoming Investor Conferences

PYXS : 1.2100 (+0.83%)
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the upcoming European...

PYXS : 1.2100 (+0.83%)
BVAXF : 0.0272 (-1.09%)
BIOV.CN : 0.0350 (unch)
SONA.CN : 0.4000 (-5.88%)
GRAL : 42.08 (+1.86%)
SNANF : 0.2935 (+1.91%)
ADPT : 10.11 (-2.03%)
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

PYXS : 1.2100 (+0.83%)
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

For Immediate ReleaseChicago, IL – April 24, 2025 – Today, Zacks Equity Research discusses Aurinia Pharmaceuticals AUPH, Heron Therapeutics HRTX, Esperion Therapeutics ESPR, Pyxis Oncology PYXS and...

ESPR : 1.1450 (-2.14%)
PSTV : 0.3071 (-2.20%)
PYXS : 1.2100 (+0.83%)
AUPH : 8.13 (-0.61%)
HRTX : 2.0000 (+3.63%)
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

PYXS : 1.2100 (+0.83%)
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

PYXS : 1.2100 (+0.83%)
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PYXS : 1.2100 (+0.83%)
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

PYXS : 1.2100 (+0.83%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.2800
2nd Resistance Point 1.2600
1st Resistance Point 1.2300
Last Price 1.2100
1st Support Level 1.1800
2nd Support Level 1.1600
3rd Support Level 1.1300

See More

52-Week High 5.3899
Fibonacci 61.8% 3.6492
Fibonacci 50% 3.1116
Fibonacci 38.2% 2.5739
Last Price 1.2100
52-Week Low 0.8332

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar